文献速递冠心病

常规侵入性策略对衰弱老年NSTEMI再梗死风险的影响:随机试验亚分析

Effects of routine invasive management on reinfarction risk in older adults with frailty and non-ST-segment elevation myocardial infarction: a subanalysis of a randomised clinical trial.
PubMed 文献 · Heart · 2025-07-28

MOSCA-FRAIL试验纳入167例≥70岁衰弱(临床衰弱量表≥4分)的NSTEMI患者,随机接受侵入性或保守策略。中位随访3年,以全因死亡为竞争风险,侵入性策略未降低再梗死风险(subdistribution HR=0.87,95%CI 0.54-1.40,p=0.56)。

要点

  • 衰弱老年NSTEMI患者中,常规侵入性策略未减少3年再梗死风险。
  • 全因死亡率高(56%),可能限制侵入性策略的获益。
  • 侵入性策略死亡率呈双相模式:前6个月较高,9个月至3年降低。

核心结论

  • 在衰弱老年NSTEMI患者中,常规侵入性管理未降低3年再梗死风险。
  • 衰弱相关的高全因死亡率可能限制侵入性管理的影响。
  • 因样本量有限和II类错误风险,结果应视为假设生成性。

研究设计与样本

  • MOSCA-FRAIL试验的亚分析,纳入167例年龄≥70岁、临床衰弱量表≥4分且患NSTEMI的成人。
  • 患者住院期间随机分配至侵入性策略(n=84)或保守策略(n=83)。
  • 主要终点为再梗死,以全因死亡为竞争事件,中位随访3年。
  • 该亚研究非预先设定。

主要发现

  • 死亡总数(93例,56%)超过首次再梗死数(32例,19%)。
  • 以死亡为竞争风险,侵入性治疗未影响再梗死风险(subdistribution HR=0.87,95%CI 0.54-1.40,p=0.56)。
  • 侵入性管理最初增加死亡风险(第131至175天间显著),随时间推移转为较低死亡风险。
  • 共观察到45次再梗死(首次和复发)。
  • 纵向轨迹证实侵入性策略未降低再梗死风险(p=0.72);死亡率呈双相模式,侵入性组前6个月较高,9个月至3年降低(整个时间依赖轨迹p=0.05)。

临床怎么用

  • 对于衰弱老年NSTEMI患者,常规侵入性策略未显示再梗死获益,决策需个体化。
  • 应充分考虑衰弱相关的高死亡风险对侵入性策略获益的潜在限制。

局限性

  • 样本量有限,存在II类错误风险。
  • 该亚分析非预先设定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials and meta-analyses indicate a reduced reinfarction risk with invasive management in older patients with non-ST-segment elevation myocardial infarction (NSTEMI). This study investigated whether similar benefits might be observed in frail patients. METHODS: The coMOrbilidades Síndrome Coronario Agudo - FRAIL (MOSCA-FRAIL) trial included 167 adults aged ≥70 years with frailty (Clinical Frailty Scale ≥4 points) and NSTEMI, who were randomised to invasive (n=84) or conservative (n=83) strategy during the index hospitalisation. The primary end point of this subanalysis was reinfarction, considering all-cause mortality as a competing event, at a 3-year median follow-up. The time to first reinfarction and all reinfarctions (first and recurrent) were considered. The substudy was not prespecified. RESULTS: The total number of deaths (93, 56%) exceeded that of first reinfarctions (32, 19%). Invasive treatment did not influence the reinfarction risk when accounting for death as a competing risk (subdistribution HR=0.87, 95% CI 0.54 to 1.40, p=0.56). An initially increased mortality risk with invasive management (significant between days 131 and 175) shifted to a lower mortality risk over time. A total of 45 reinfarctions (first and recurrent) were observed. The longitudinal trajectories corroborated that the invasive strategy did not reduce the risk of reinfarction over time (p=0.72). However, mortality followed a biphasic pattern, with higher mortality in the invasive group during the first 6 months and a reduction between 9 months and 3 years (p=0.05 for the entire time-dependent trajectory). The win ratio for the invasive strategy versus the conservative strategy was 1.08 (95% CI 0.72 to 1.63, p=0.70). CONCLUSIONS: In older adults with frailty and NSTEMI, routine invasive management did not reduce the reinfarction risk at a 3-year follow-up. The high all-cause mortality associated with frailty may limit the impact of invasive management. Due to the limited sample size and risk for type II error, these findings should be considered hypothesis-generating. TRIAL REGISTRATION NUMBER: NCT03208153.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Sanchis, Bueno, Martí Sánchez, et al. Effects of routine invasive management on reinfarction risk in older adults with frailty and non-ST-segment elevation myocardial infarction: a subanalysis of a randomised clinical trial. Heart. 2025. PMID: 39922692. doi:10.1136/heartjnl-2024-325254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。